Literature DB >> 11290617

Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants.

I Volpi1, K Perruccio, A Tosti, M Capanni, L Ruggeri, S Posati, F Aversa, A Tabilio, L Romani, M F Martelli, A Velardi.   

Abstract

In human leukocyte antigen haplotype-mismatched transplantation, extensive T-cell depletion prevents graft-versus-host disease (GVHD) but delays immune recovery. Granulocyte colony-stimulating factor (G-CSF) is given to donors to mobilize stem cells and to recipients to ensure engraftment. Studies have shown that G-CSF promotes T-helper (Th)-2 immune deviation which, unlike Th1 responses, does not protect against intracellular pathogens and fungi. The effect of administration of G-CSF to recipients of mismatched hematopoietic transplants with respect to transplantation outcome and functional immune recovery was investigated. In 43 patients with acute leukemia who received G-CSF after transplantation, the engraftment rate was 95%. However, the patients had a long-lasting type 2 immune reactivity, ie, Th2-inducing dendritic cells not producing interleukin 12 (IL-12) and high frequencies of IL-4- and IL-10-producing CD4(+) cells not expressing the IL-12 receptor beta(2) chain. Similar immune reactivity patterns were observed on exposure of donor cells to G-CSF. Elimination of postgrafting administration of G-CSF in a subsequent series of 36 patients with acute leukemia, while not adversely affecting engraftment rate (93%), resulted in the anticipated appearance of IL-12-producing dendritic cells (1-3 months after transplantation versus > 12 months in transplant recipients given G-CSF), of CD4(+) cells of a mixed Th0/Th1 phenotype, and of antifungal T-cell reactivity in vitro. Moreover, CD4(+) cell counts increased in significantly less time. Finally, elimination of G-CSF-mediated immune suppression did not significantly increase the incidence of GVHD (< 15%). Thus, this study found that administration of G-CSF to recipients of T-cell-depleted hematopoietic transplants was associated with abnormal antigen-presenting cell functions and T-cell reactivity. Elimination of postgrafting administration of G-CSF prevented immune dysregulation and accelerated functional immune recovery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290617     DOI: 10.1182/blood.v97.8.2514

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  Am J Transl Res       Date:  2011-09-10       Impact factor: 4.060

Review 2.  Regulation of neutrophil functions by proinflammatory cytokines.

Authors:  Takayuki Kato; Seiichi Kitagawa
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

Review 3.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

Review 4.  Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy.

Authors:  Paolo Anderlini; Richard Champlin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation.

Authors:  Coco de Koning; Julie-Anne Gabelich; Jurgen Langenhorst; Rick Admiraal; Jurgen Kuball; Jaap Jan Boelens; Stefan Nierkens
Journal:  Blood Adv       Date:  2018-03-13

6.  Haploidentical stem cell transplantation for acute leukemia.

Authors:  F Aversa; A Terenzi; R Felicini; A Carotti; F Falcinelli; A Tabilio; A Velardi; M F Martelli
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Authors:  Rakesh K Singh; Michelle L Varney; Cheryl Leutzinger; Julie M Vose; Philip J Bierman; Suleyman Buyukberber; Kazuhiko Ino; Kevin Loh; Craig Nichols; David Inwards; Robert Rifkin; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2007-04-20       Impact factor: 4.932

8.  Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies.

Authors:  Giuseppina Bonanno; Annabella Procoli; Andrea Mariotti; Maria Corallo; Alessandro Perillo; Silvio Danese; Raimondo De Cristofaro; Giovanni Scambia; Sergio Rutella
Journal:  J Transl Med       Date:  2010-11-09       Impact factor: 5.531

Review 9.  Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases.

Authors:  Franco Aversa; Massimo F Martelli
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

10.  Clinical uses of GM-CSF, a critical appraisal and update.

Authors:  Martha Arellano; Sagar Lonial
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.